Background
Background Relapse rates may be as Relapse rates may be as high as 50% in people with major high as 50% in people with major depressive disorder (MDD) previously depressive disorder (MDD) previously treated to remission. treated to remission.
Aims Aims Duloxetine, an inhibitor of
Duloxetine, an inhibitor of serotonin and noradrenaline reuptake that serotonin and noradrenaline reuptake that is licensed in Europe, the USA and is licensed in Europe, the USA and elsewhere for the treatment of depressive elsewhere for the treatment of depressive episodes, was evaluated with regard to its episodes, was evaluated with regard to its efficacy, safety and tolerability in the efficacy, safety and tolerability in the prevention of relapse of MDD. prevention of relapse of MDD.
Method Method Adult out-patients with MDD
Adult out-patients with MDD received duloxetine (60 mg daily) for12 received duloxetine (60 mg daily) for12 weeks ( weeks (n n¼533).Patients who responded 533).Patients who responded to the drug were then randomised to to the drug were then randomised to duloxetine (60 mgdaily) ( duloxetine (60 mgdaily) (n n¼136) orplacebo 136) orplacebo ( (n n¼142) for 26 weeks.The primary 142) for 26 weeks.The primary measure of efficacy was time to relapse. measure of efficacy was time to relapse.
Results

Results Patients who received duloxe-
Patients who received duloxetine (60 mg daily) experienced significantly tine (60 mg daily) experienced significantly longer times to relapse of MDD, and longer times to relapse of MDD, and better efficacy, global well-being, and better efficacy, global well-being, and quality-of-life outcomes compared with quality-of-life outcomes compared with patients who received placebo.It should patients who received placebo.It should be noted that adverse events which occur be noted that adverse events which occur in discontinuation may mimic some signs of in discontinuation may mimic some signs of depressive relapse, and were not depressive relapse, and were not specifically elicited in this study. specifically elicited in this study.
Conclusions
Conclusions Duloxetine (60 mg daily) Duloxetine (60 mg daily) is effective in the prevention of relapse of is effective in the prevention of relapse of MDD during continuation treatment. MDD during continuation treatment. Relapse, namely the re-emergence of Relapse, namely the re-emergence of depressive symptoms following successful depressive symptoms following successful acute treatment of major depressive disoracute treatment of major depressive disorder (MDD), is a significant clinical concern der (MDD), is a significant clinical concern (Segal (Segal et al et al, 2003) . The current guidelines , 2003). The current guidelines suggest that antidepressant therapy should suggest that antidepressant therapy should be maintained for between 9 months and 1 be maintained for between 9 months and 1 year (World Health Organization, 1989) . year (World Health Organization, 1989) . Failure to adhere to these guidelines may Failure to adhere to these guidelines may increase the risk of relapse by 70% (Melfi increase the risk of relapse by 70% (Melfi et al et al, 1998) . Preclinical studies indicate that , 1998). Preclinical studies indicate that duloxetine is a potent dual reuptake inhibiduloxetine is a potent dual reuptake inhibitor with similar affinities for serotonin and tor with similar affinities for serotonin and noradrenaline transporters (Bymaster noradrenaline transporters (Bymaster et al et al, , 2001) , and it has been shown to be 2001), and it has been shown to be efficacious in the acute treatment of MDD efficacious in the acute treatment of MDD (Detke (Detke et al et al, 2002) . To determine the , 2002). To determine the efficacy of duloxetine in preventing efficacy of duloxetine in preventing relapse of MDD, and to assess its longrelapse of MDD, and to assess its longterm safety and tolerability, a randomised term safety and tolerability, a randomised relapse prevention study was conducted. relapse prevention study was conducted. We postulated that MDD patients who We postulated that MDD patients who showed clinically significant symptom showed clinically significant symptom improvement in response to duloxetine improvement in response to duloxetine (60 mg daily) during 12 weeks of open-label (60 mg daily) during 12 weeks of open-label treatment would have a significantly longer treatment would have a significantly longer time to relapse and lower relapse rates time to relapse and lower relapse rates when maintained on duloxetine (60 mg when maintained on duloxetine (60 mg daily) compared with patients who were daily) compared with patients who were randomised to placebo for 6 months. randomised to placebo for 6 months.
Declaration of interest
METHOD METHOD
Selection of participants Selection of participants
All of the study participants (both men All of the study participants (both men and women) were at least 18 years of age. and women) were at least 18 years of age. Ethics review boards at each site approved Ethics review boards at each site approved the study protocol before the study began the study protocol before the study began at that site. Written informed consent at that site. Written informed consent was provided by all participants before was provided by all participants before any study procedures were initiated. All any study procedures were initiated. All of the participants met the DSM-IV of the participants met the DSM-IV (American Psychiatric Association, 1994) (American Psychiatric Association, 1994) criteria for MDD without psychotic criteria for MDD without psychotic features as assessed using the Mini features as assessed using the Mini International Neuropsychiatric Interview International Neuropsychiatric Interview (MINI; Sheehan (MINI; Sheehan et al et al, 1998) . Baseline , 1998). Baseline disease severity was assessed using the disease severity was assessed using the 17-item Hamilton Rating Scale for 17-item Hamilton Rating Scale for Depression (HRSD; Hamilton, 1960) and Depression (HRSD; Hamilton, 1960) and the Clinical Global Impression -Severity the Clinical Global Impression -Severity (CGI-S) scale (Guy, 1976) . At both the (CGI-S) scale (Guy, 1976) . At both the screening and second study visits, all study screening and second study visits, all study participants were required to meet the entry participants were required to meet the entry criteria of HRSD criteria of HRSD 17 17 score score 5 518 and CGI-S 18 and CGI-S score score 5 54, indicating at least moderate de-4, indicating at least moderate depression. In addition, participants must pression. In addition, participants must have had at least one other major have had at least one other major depressive episode before the episode that depressive episode before the episode that was being experienced at the time of entry was being experienced at the time of entry to the study. to the study.
Reasons for exclusion from the study Reasons for exclusion from the study included the following: having a current included the following: having a current and primary Axis I disorder other than and primary Axis I disorder other than MDD; anxiety disorder as a primary diag-MDD; anxiety disorder as a primary diagnosis within 1 year of entry to the study; nosis within 1 year of entry to the study; treatment-resistant depression; serious treatment-resistant depression; serious suicidal risk; and serious medical illness. suicidal risk; and serious medical illness.
Study design Study design
The design was a randomised activeThe design was a randomised activetreatment lead-in double-blind placebotreatment lead-in double-blind placebocontrolled multicentre parallel-group study controlled multicentre parallel-group study of out-patients who met the DSM-IV criof out-patients who met the DSM-IV criteria for MDD. The study was conducted teria for MDD. The study was conducted in France, Italy, Spain and the USA. The in France, Italy, Spain and the USA. The study design (Fig. 1 ) was similar to that study design (Fig. 1 ) was similar to that of previous relapse-prevention studies of previous relapse-prevention studies (Fava (Fava et al et al, 2002; Schmidt , 2002; Schmidt et al et al, 2002) . , 2002). During the initial screening phase and During the initial screening phase and before the second visit (week 0), all before the second visit (week 0), all participants underwent screening tests in participants underwent screening tests in addition to both psychiatric and physical addition to both psychiatric and physical examinations. examinations.
Acute phase Acute phase
All of the participants who met the All of the participants who met the enrolment criteria received open-label enrolment criteria received open-label duloxetine (60 mg daily) for 12 weeks. If duloxetine (60 mg daily) for 12 weeks. If it was necessary to address problems with it was necessary to address problems with regard to tolerability, investigators could regard to tolerability, investigators could reduce the patient's daily duloxetine dose reduce the patient's daily duloxetine dose to 30 mg until week 4. to 30 mg until week 4.
Continuation phase Continuation phase
Participants were eligible to enter the contiParticipants were eligible to enter the continuation phase if they met the following nuation phase if they met the following criteria: HRSD criteria: HRSD 17 17 score score 4 49; CGI-S score 9; CGI-S score 4 42; and no longer meeting the DSM-IV 2; and no longer meeting the DSM-IV criteria for MDD in weeks 10 and 12 of criteria for MDD in weeks 10 and 12 of the acute phase. Eligible patients were ranthe acute phase. Eligible patients were randomised at week 12 to either duloxetine domised at week 12 to either duloxetine (60 mg daily) or placebo for 26 weeks. (60 mg daily) or placebo for 26 weeks. Patients who were randomised to the Patients who were randomised to the placebo arm were tapered with duloxetine placebo arm were tapered with duloxetine 3 4 6 3 4 6
B R I T I S H J O UR N A L O F P SYC HI AT RY B R I T I S H J O UR N A L O F P S YC H I AT RY
Duloxetine in the prevention of relapse Duloxetine in the prevention of relapse of major depressive disorder of major depressive disorder Double-blind placebo-controlled study Double-blind placebo-controlled study (30 mg daily) for 1 week in a double-blind (30 mg daily) for 1 week in a double-blind manner. All continuing participants were manner. All continuing participants were assessed during at least nine scheduled visits assessed during at least nine scheduled visits from week 13 to week 38. Re-emergence of from week 13 to week 38. Re-emergence of depressive symptoms at any time was depressive symptoms at any time was defined as an HRSD defined as an HRSD 17 17 score of score of 5 512, 12, prompting weekly visits until an HRSD prompting weekly visits until an HRSD 17 17 score of score of 5 512 was obtained or the patient 12 was obtained or the patient met the criteria for relapse. Relapse was met the criteria for relapse. Relapse was defined in the protocol as an increased defined in the protocol as an increased CGI-S score of CGI-S score of 5 52 points compared with 2 points compared with that obtained in week 12, as well as that obtained in week 12, as well as meeting the MINI depression module crimeeting the MINI depression module criteria for MDD at two consecutive visits at teria for MDD at two consecutive visits at least 2 weeks apart. Participants who least 2 weeks apart. Participants who experienced a relapse were offered the experienced a relapse were offered the option of entry into the rescue phase. option of entry into the rescue phase.
Rescue phase Rescue phase
Participants who experienced relapse durParticipants who experienced relapse during the continuation phase were offered ing the continuation phase were offered the option of entry into the double-blind the option of entry into the double-blind rescue phase at the investigator's discretion. rescue phase at the investigator's discretion. Relapsed patients who had been randomRelapsed patients who had been randomised to placebo were re-initiated on ised to placebo were re-initiated on duloxetine (60 mg daily). Relapsed patients duloxetine (60 mg daily). Relapsed patients who had been randomised to duloxetine who had been randomised to duloxetine (60 mg daily) had their dose of duloxetine (60 mg daily) had their dose of duloxetine increased (to 60 mg twice daily). The rescue increased (to 60 mg twice daily). The rescue phase will be discussed in detail in a later phase will be discussed in detail in a later paper. paper.
Follow-up phase Follow-up phase
All of the participants entered the followAll of the participants entered the followup phase after either completing or up phase after either completing or discontinuing either the continuation phase discontinuing either the continuation phase or the rescue phase. If patients were or the rescue phase. If patients were receiving duloxetine, their duloxetine dose receiving duloxetine, their duloxetine dose was reduced by 50% for 3 days. Placebowas reduced by 50% for 3 days. Placebotreated patients continued to receive treated patients continued to receive placebo. In both cases, participants received placebo. In both cases, participants received no study drug after the third day of the no study drug after the third day of the follow-up phase. After approximately 1 follow-up phase. After approximately 1 3 4 7 3 4 7 AUTHOR'S PROOF AUTHOR'S PROOF Fig. 1 Patient disposition flow chart.Two of the 280 participants who met the entry criteria for randomisation chose not to continue in the study, and are therefore Patient disposition flow chart.Two of the 280 participants who met the entry criteria for randomisation chose not to continue in the study, and are therefore accounted for in acute-phase discontinuation, even though they completed the acute phase.Of the 200 participants who entered the follow-up phase (continuation phase: accounted for in acute-phase discontinuation, even though they completed the acute phase.Of the 200 participants who entered the follow-up phase (continuation phase:
duloxetine (60 mg daily) ( duloxetine (60 mg daily) (n n¼76), placebo ( 76), placebo (n n¼54); rescue phase: duloxetine (60 mg daily) ( 54); rescue phase: duloxetine (60 mg daily) (n n¼47), duloxetine (60 mg twice daily) ( 47), duloxetine (60 mg twice daily) (n n¼23)), 193 individuals completed the 23)), 193 individuals completed the phase. phase.
week, efficacy and safety data were week, efficacy and safety data were collected. collected.
Assessments Assessments
Efficacy Efficacy
The primary efficacy measure was time The primary efficacy measure was time from randomisation to relapse for particifrom randomisation to relapse for participants during the continuation phase. pants during the continuation phase. 
Safety and tolerability Safety and tolerability
During all of the treatment phases, safety During all of the treatment phases, safety and tolerability were evaluated by collecting and tolerability were evaluated by collecting and reporting the incidence, severity and and reporting the incidence, severity and seriousness of adverse events, the reasons seriousness of adverse events, the reasons for discontinuation, vital signs, body for discontinuation, vital signs, body weight and laboratory investigation results. weight and laboratory investigation results.
Statistical methods Statistical methods
The primary efficacy analysis compared the The primary efficacy analysis compared the time from randomisation to relapse for time from randomisation to relapse for patients who were receiving duloxetine patients who were receiving duloxetine (60 mg daily) and patients who were on (60 mg daily) and patients who were on placebo, using the log-rank test. Time to placebo, using the log-rank test. Time to relapse was defined as the number of days relapse was defined as the number of days from the randomisation date to the relapse from the randomisation date to the relapse date. The analysis included as patients date. The analysis included as patients experiencing relapse only those participants experiencing relapse only those participants who satisfied the protocol definition of who satisfied the protocol definition of relapse described above. relapse described above.
During the continuation phase, other During the continuation phase, other continuous measures were compared for continuous measures were compared for duloxetine duloxetine v v. placebo by analysis of covar-. placebo by analysis of covariance (ANCOVA), analysis of variance iance (ANCOVA), analysis of variance (ANOVA) and/or mixed-model repeated-(ANOVA) and/or mixed-model repeatedmeasures analysis (Mallinckrodt measures analysis (Mallinckrodt et al et al, , 2001 ). Unless otherwise specified, mean 2001). Unless otherwise specified, mean changes from baseline to end-point were changes from baseline to end-point were compared, the baseline and end-point being compared, the baseline and end-point being defined as the initial and last observations defined as the initial and last observations respectively during each study phase. The respectively during each study phase. The ANCOVA model included baseline, treat-ANCOVA model included baseline, treatment and investigator, the ANOVA model ment and investigator, the ANOVA model included treatment and investigator, and included treatment and investigator, and the mixed-model repeated-measures analythe mixed-model repeated-measures analysis included baseline, visit, treatment, invessis included baseline, visit, treatment, investigator, treatment tigator, treatment6 6visit interaction and visit interaction and baseline baseline6 6visit interaction. For categorical visit interaction. For categorical measures, treatments were compared by measures, treatments were compared by Fisher's exact test. Fisher's exact test.
During the acute phase, baseline and During the acute phase, baseline and end-point values were compared within end-point values were compared within groups using the paired groups using the paired t t-test. 
RESULTS RESULTS
Study flow Study flow
The study design is summarised in the The study design is summarised in the flow chart shown in Fig. 1 . A total of 533 flow chart shown in Fig. 1 . A total of 533 participants met the enrolment criteria participants met the enrolment criteria during the screening phase, entered the during the screening phase, entered the acute phase of the study, and received acute phase of the study, and received open-label duloxetine (60 mg daily) for up open-label duloxetine (60 mg daily) for up to 12 weeks. Of these, 280 participants to 12 weeks. Of these, 280 participants (52.5%) met the response criteria for (52.5%) met the response criteria for entering the continuation phase. All but 2 entering the continuation phase. All but 2 participants ( participants (n n¼278) agreed to enter the 278) agreed to enter the double-blind continuation phase. In total, double-blind continuation phase. In total, 142 patients were randomised to placebo 142 patients were randomised to placebo and 136 patients were randomised to and 136 patients were randomised to duloxetine (60 mg daily). duloxetine (60 mg daily).
Baseline characteristics of patients Baseline characteristics of patients
There were no significant differences in There were no significant differences in baseline characteristics (ethnic origin, age baseline characteristics (ethnic origin, age or gender) between patients who received or gender) between patients who received duloxetine (60 mg daily) and those who duloxetine (60 mg daily) and those who received placebo during the continuation received placebo during the continuation phase (Table 1) . At the time of randomisphase (Table 1) . At the time of randomisation in week 12 (and therefore at baseline ation in week 12 (and therefore at baseline for the continuation phase of the study) for the continuation phase of the study) there were no significant differences there were no significant differences between participants who were randomised between participants who were randomised to the two treatment groups with regard to to the two treatment groups with regard to HRSD HRSD 17 17 total score, CGI-S score, PGI-I total score, CGI-S score, PGI-I score and visual analogue scale overall score. score and visual analogue scale overall score.
Efficacy Efficacy
Patients who received duloxetine (60 mg Patients who received duloxetine (60 mg daily) during the continuation phase had a daily) during the continuation phase had a significantly longer time to relapse than significantly longer time to relapse than patients who were on placebo ( patients who were on placebo (P P¼0.004). 0.004). The Kaplan-Meier plot of time to relapse The Kaplan-Meier plot of time to relapse showed that patients on duloxetine sepashowed that patients on duloxetine separated from those on placebo as early as 1 rated from those on placebo as early as 1 month after randomisation (Fig. 2) , and that month after randomisation (Fig. 2) , and that this separation increased over time. At the this separation increased over time. At the end of the study, the estimated probabilities end of the study, the estimated probabilities of relapse were 38.3% and 19.7% for paof relapse were 38.3% and 19.7% for patients who received placebo and duloxetine tients who received placebo and duloxetine (60 mg daily) respectively. Significantly few-(60 mg daily) respectively. Significantly fewer patients who received duloxetine (60 mg er patients who received duloxetine (60 mg daily) relapsed compared with patients who daily) relapsed compared with patients who received placebo ( received placebo (P P5 50.05) ( Table 2) . 0.05) ( Table 2 ). In total, 26 participants (6 patients In total, 26 participants (6 patients from the duloxetine (60 mg daily) treatment from the duloxetine (60 mg daily) treatment group and 20 patients from the placebo group and 20 patients from the placebo treatment group) entered the rescue phase treatment group) entered the rescue phase without completely satisfying the protocol's without completely satisfying the protocol's criteria for the definition of relapse. They criteria for the definition of relapse. They did have two consecutive visits which met did have two consecutive visits which met the requirements for relapse, but the second the requirements for relapse, but the second visit occurred less than 2 weeks after the visit occurred less than 2 weeks after the 3 4 8 3 4 8 AUTHOR'S PROOF AUTHOR'S PROOF , 17-item Hamilton Rating Scale for Depression; CGI^S, Clinical Global Impression^Severity. 1. At baseline (week12) there were no significant differences in patient characteristics between individuals randomised 1. At baseline (week 12) there were no significant differences in patient characteristics between individuals randomised to duloxetine (60 mg daily) and those randomised to the placebo group during the continuation phase. to duloxetine (60 mg daily) and those randomised to the placebo group during the continuation phase. 2. 60 mg daily. 2. 60 mg daily. first one. They were entered into the rescue first one. They were entered into the rescue phase because the investigator judged them phase because the investigator judged them to require additional therapy, independent to require additional therapy, independent of the protocol criteria. However, their of the protocol criteria. However, their average HRSD average HRSD 17 17 total score before entry total score before entry into the rescue phase was 18.8. These into the rescue phase was 18.8. These patients were not considered to be relapsed patients were not considered to be relapsed in the primary efficacy analysis. This is a in the primary efficacy analysis. This is a statistically conservative approach. If these statistically conservative approach. If these 26 patients had been included as relapsed 26 patients had been included as relapsed in the log-rank test, the relative advantage in the log-rank test, the relative advantage of duloxetine in preventing relapse comof duloxetine in preventing relapse compared with placebo would have been even pared with placebo would have been even greater (Table 2) . greater (Table 2) .
Secondary efficacy measures Secondary efficacy measures
At the end-point of the acute phase, patients At the end-point of the acute phase, patients who were receiving duloxetine (60 mg who were receiving duloxetine (60 mg daily) had a response rate of 68% (defined daily) had a response rate of 68% (defined as a reduction of as a reduction of 5 550% in HRSD 50% in HRSD 17 17 total total score) and a remission rate of 53% (defined score) and a remission rate of 53% (defined as an HRSD as an HRSD 17 17 total score of total score of 4 47) (Table 3) . 7) (Table 3) . Compared with baseline (week 0), patients' Compared with baseline (week 0), patients' HRSD HRSD 17 17 total scores had decreased after 1 total scores had decreased after 1 week of duloxetine (60 mg daily), and were week of duloxetine (60 mg daily), and were reduced at all subsequent visits ( reduced at all subsequent visits (P P5 50.005) 0.005) throughout the acute phase for patients throughout the acute phase for patients who remained in the study (Fig. 3) . who remained in the study (Fig. 3) . During the continuation phase, patients During the continuation phase, patients who received duloxetine (60 mg daily) who received duloxetine (60 mg daily) experienced less worsening of depressive experienced less worsening of depressive symptoms compared with patients who resymptoms compared with patients who received placebo ( ceived placebo (P P5 50.01), as assessed by 0.01), as assessed by their change in HRSD their change in HRSD 17
17 total scores at all total scores at all time points from week 14 to week 38 time points from week 14 to week 38 (Fig. 3) . The 29 patients who received du- (Fig. 3) . The 29 patients who received duloxetine (60 mg daily) and the 58 patients loxetine (60 mg daily) and the 58 patients who received placebo who satisfied the prowho received placebo who satisfied the protocol's criteria for relapse (see Method) or tocol's criteria for relapse (see Method) or who were judged by the investigator to who were judged by the investigator to have relapsed (as described earlier) were have relapsed (as described earlier) were then offered the option of entry into the then offered the option of entry into the study's rescue phase (Fig. 1) . Response study's rescue phase (Fig. 1) . Response and remission rates at the end-point of the and remission rates at the end-point of the rescue phase are shown in Table 3 . rescue phase are shown in Table 3 .
The mean change from baseline to endThe mean change from baseline to endpoint for multiple secondary efficacy point for multiple secondary efficacy measures was also examined during the measures was also examined during the continuation phase. Patients who received continuation phase. Patients who received duloxetine (60 mg daily) achieved or duloxetine (60 mg daily) achieved or maintained significantly greater improvemaintained significantly greater improvement in physical and emotional symptoms ment in physical and emotional symptoms (on all measures except visual analogue (on all measures except visual analogue scales for overall pain) compared with scales for overall pain) compared with patients who received placebo (Table 4) . patients who received placebo (Table 4 ). In addition, for all visits from week 14 to In addition, for all visits from week 14 to week 38, duloxetine (60 mg daily) treatweek 38, duloxetine (60 mg daily) treatment was superior to placebo treatment in ment was superior to placebo treatment in terms of patients' PGI-I scores. terms of patients' PGI-I scores.
Tolerability and adverse events Tolerability and adverse events
Acute phase Acute phase
Investigators rated the severity of adverse Investigators rated the severity of adverse events as mild, moderate or severe based events as mild, moderate or severe based on the patient's discomfort, the health on the patient's discomfort, the health risk and/or interference with the patient's risk and/or interference with the patient's activity. The five most frequently reported activity. The five most frequently reported treatment-linked adverse events were nautreatment-linked adverse events were nausea ( sea (n n¼191 (36%); 90% mild to moderate 191 (36%); 90% mild to moderate severity), headache ( severity), headache (n n¼108 (20%); 86% 108 (20%); 86% mild to moderate severity); dry mouth mild to moderate severity); dry mouth ( (n n¼96 (18%); 96% mild to moderate 96 (18%); 96% mild to moderate severity); somnolence ( severity); somnolence (n n¼72 (14%); 85% 72 (14%); 85% mild to moderate severity) and insomnia mild to moderate severity) and insomnia ( (n n¼56; (11%); 79% mild to moderate 56; (11%); 79% mild to moderate severity). Adverse events that were reported severity). Adverse events that were reported as reasons for discontinuation of treatment as reasons for discontinuation of treatment during the acute phase (expressed as during the acute phase (expressed as number of patients and percentage for number of patients and percentage for whom 'adverse event' was given as the whom 'adverse event' was given as the reason for discontinuation) included nausea reason for discontinuation) included nausea ( (n n¼11; 2.1%), somnolence ( 11; 2.1%), somnolence (n n¼4; 0.8%), 4; 0.8%), suicide attempts ( suicide attempts (n n¼3; 0.6%) and vomiting 3; 0.6%) and vomiting ( (n n¼3; 0.6%). In addition, one patient died 3; 0.6%). In addition, one patient died by suicide on day 16 during the acute phase by suicide on day 16 during the acute phase of the study. The investigator judged the of the study. The investigator judged the suicide to be unrelated to the study drug. suicide to be unrelated to the study drug.
Continuation phase Continuation phase
There were no statistically significant difThere were no statistically significant differences in the rate of adverse event reports ferences in the rate of adverse event reports between patients who received duloxetine between patients who received duloxetine and those who received placebo. During and those who received placebo. During the continuation phase, anxiety, cholethe continuation phase, anxiety, cholelithiasis, spastic colon, ejaculation failure lithiasis, spastic colon, ejaculation failure and gastroesophageal reflux disease were and gastroesophageal reflux disease were reported by 1 patient each as reasons reported by 1 patient each as reasons for discontinuation of duloxetine (60 mg for discontinuation of duloxetine (60 mg daily) ( daily) (n n¼5; 3.7%). Back pain, hypomania, 5; 3.7%). Back pain, hypomania, insomnia, abnormal liver function tests and insomnia, abnormal liver function tests and paraesthesia were each reported by 1 paraesthesia were each reported by 1 patient who was taking placebo ( patient who was taking placebo (n n¼5; 5; 3.5%) as reasons for study discontinuation. 3.5%) as reasons for study discontinuation.
Follow-up phase Follow-up phase
No adverse events were reported as reasons No adverse events were reported as reasons for discontinuation during the follow-up for discontinuation during the follow-up 3 4 9 3 4 9 AUTHOR'S PROOF AUTHOR'S PROOF Fig. 2 Kaplan^Meier plot of time from randomisation to relapse.The estimated probability of relapse Kaplan^Meier plot of time from randomisation to relapse.The estimated probability of relapse following randomisation was compared for participants who received either duloxetine (60 mg daily) or placebo following randomisation was compared for participants who received either duloxetine (60 mg daily) or placebo during the continuation phase using the log^rank test.The treatment groups separated as early as 1 month during the continuation phase using the log^rank test.The treatment groups separated as early as 1 month after randomisation. Duloxetine-treated patients had a longer time to relapse than patients who received after randomisation. Duloxetine-treated patients had a longer time to relapse than patients who received placebo ( placebo (P P¼0.004). 0.004). phase. For patients who entered the follow-up phase. For patients who entered the follow-up phase from the continuation phase, adverse phase from the continuation phase, adverse event rates of more than 2% were reported event rates of more than 2% were reported by duloxetine-treated patients for the followby duloxetine-treated patients for the following: dizziness (13.2%); insomnia (3.9%); ing: dizziness (13.2%); insomnia (3.9%); headache, abnormal dreams, asthenia, tinniheadache, abnormal dreams, asthenia, tinnitus and fatigue (2.6% each). Abdominal pain tus and fatigue (2.6% each). Abdominal pain (upper) and pruritis were each reported by (upper) and pruritis were each reported by one placebo-treated patient. one placebo-treated patient.
Cardiovascular safety Cardiovascular safety
There were no clinically significant mean There were no clinically significant mean changes in blood pressure or heart rate changes in blood pressure or heart rate between baseline and the end-point in any between baseline and the end-point in any of the groups in any of the study phases. of the groups in any of the study phases.
Acute phase Acute phase
There was no significant mean change in There was no significant mean change in patients' diastolic blood pressure between patients' diastolic blood pressure between baseline and the end-point during this baseline and the end-point during this phase. Average heart rate increased by phase. Average heart rate increased by approximately 1.7 beats/minute ( approximately 1.7 beats/minute (P P5 50.005) 0.005) and average systolic blood pressure and average systolic blood pressure increased by approximately 1.3 mmHg increased by approximately 1.3 mmHg ( (P P5 50.05). 0.05).
Continuation phase Continuation phase
During this phase there were no sigDuring this phase there were no significant differences in mean changes in nificant differences in mean changes in systolic blood pressure or heart rate systolic blood pressure or heart rate between patients who received duloxetine between patients who received duloxetine (60 mg daily) and those who received (60 mg daily) and those who received placebo. Patients who received duloxetine placebo. Patients who received duloxetine (60 mg daily) showed increased mean (60 mg daily) showed increased mean changes in diastolic blood pressure comchanges in diastolic blood pressure compared with patients who pared with patients who received placebo received placebo (2.0 mmHg (2.0 mmHg v v. . 7 71.0 mmHg; 1.0 mmHg; P P¼0.005). 0.005).
Laboratory values Laboratory values
There were no clinically significant or There were no clinically significant or persistent changes in laboratory results for persistent changes in laboratory results for patients who received duloxetine during patients who received duloxetine during any of the study phases. Mild to moderate any of the study phases. Mild to moderate increases in serum aspartate aminotransferincreases in serum aspartate aminotransferase or alanine aminotransferase levels were ase or alanine aminotransferase levels were reported for 37 patients during the acute reported for 37 patients during the acute phase. During the continuation phase, 4 phase. During the continuation phase, 4 placebo-treated patients and 7 duloxetineplacebo-treated patients and 7 duloxetinetreated patients had elevated alanine treated patients had elevated alanine aminotransferase levels, and 3 placeboaminotransferase levels, and 3 placebotreated patients and 4 duloxetine-treated treated patients and 4 duloxetine-treated patients had elevated aspartate aminotranspatients had elevated aspartate aminotransferase levels. In all cases, the elevated hepaferase levels. In all cases, the elevated hepatic enzyme levels resolved spontaneously tic enzyme levels resolved spontaneously and the patients remained in the study. and the patients remained in the study. During the continuation phase, one patient During the continuation phase, one patient who was treated with placebo for 14 weeks who was treated with placebo for 14 weeks experienced concomitant elevated transaexperienced concomitant elevated transaminase and bilirubin levels, with no minase and bilirubin levels, with no evidence of haemolysis or hyperbilirubinevidence of haemolysis or hyperbilirubinaemia. The patient was withdrawn from aemia. The patient was withdrawn from the study and the elevated transaminase the study and the elevated transaminase and bilirubin levels resolved spontaneously and bilirubin levels resolved spontaneously within 1 month. within 1 month. One female patient had an increased One female patient had an increased serum prolactin level (36.5 serum prolactin level (36.5 m mg/l; normal g/l; normal range 1.39-54.2 range 1.39-54.2 m mg/l) 2 days before starting g/l) 2 days before starting the study drug in the acute phase, and was the study drug in the acute phase, and was prescribed nomegestrol acetate for 173 prescribed nomegestrol acetate for 173 days. At the time of randomisation to dudays. At the time of randomisation to duloxetine (60 mg daily) her prolactin level loxetine (60 mg daily) her prolactin level was still elevated (35.6 mcg/l). This patient was still elevated (35.6 mcg/l). This patient completed the continuation and follow-up completed the continuation and follow-up phases of the study. phases of the study.
DISCUSSION DISCUSSION
In addition to the undoubted impact of In addition to the undoubted impact of depression on individuals and their social depression on individuals and their social networks, the effective treatment of networks, the effective treatment of depression, including the prevention of subdepression, including the prevention of subsequent depressive relapses, has important sequent depressive relapses, has important economic benefits. In 2000, the estimated economic benefits. In 2000, the estimated total cost of adult depression in England total cost of adult depression in England was over £9 billion (in excess of US$ 15.5 was over £9 billion (in excess of US$ 15.5 billion), with nearly 110 million working billion), with nearly 110 million working days lost and 2615 deaths (Thomas & days lost and 2615 deaths (Thomas & Morris, 2003) . In the USA, during the same Morris, 2003) . In the USA, during the same year the economic burden of depression year the economic burden of depression was estimated to be over US$ 83 billion was estimated to be over US$ 83 billion (£47 billion) (Greenberg (£47 billion) (Greenberg et al et al, 2003) . , 2003).
Continuing treatment Continuing treatment
Once an antidepressant has proved to be efOnce an antidepressant has proved to be effective for and well tolerated by an individfective for and well tolerated by an individual patient during the acute treatment of a ual patient during the acute treatment of a depressive episode, treatment guidelines depressive episode, treatment guidelines (e.g. World Health Organization, 1989) re-(e.g. World Health Organization, 1989) recommend continuing treatment with that commend continuing treatment with that antidepressant for at least a further 6 antidepressant for at least a further 6 months to minimise the risk of depressive months to minimise the risk of depressive 3 5 0 3 5 0 AUTHOR'S PROOF AUTHOR'S PROOF , 17-item Hamilton Rating Scale for Depression. 1. Response was defined as a reduction in HRSD 1. Response was defined as a reduction in HRSD 17 17 total score of total score of 5 550% between baseline and end-point. 50% between baseline and end-point. 2. Remission was defined as an HRSD 2. Remission was defined as an HRSD 17 17 total score of total score of 4 47 at end-point. 7 at end-point.
Fig. 3 Fig. 3 HRSD HRSD 17 17 total scores during the acute and continuation phases. In total, 533 patients who were total scores during the acute and continuation phases. In total, 533 patients who were diagnosed with major depressive disorder received open-label duloxetine (60 mg daily) during the acute phase. diagnosed with major depressive disorder received open-label duloxetine (60 mg daily) during the acute phase.
In the continuation phase, patients who met the protocol criteria in week 12 were randomised to either In the continuation phase, patients who met the protocol criteria in week 12 were randomised to either continue duloxetine (60 mg daily) ( continue duloxetine (60 mg daily) (n n¼136) or to receive placebo ( 136) or to receive placebo (n n¼142) in a double-blind manner. Acute phase: 142) in a double-blind manner. Acute phase:
HRSD HRSD 17 17 total score (least square mean) decreased from week 1 to week 12 ( total score (least square mean) decreased from week 1 to week 12 (P P4 40.001). Continuation phase: 0.001). Continuation phase:
HRSD HRSD 17 17 total score (least square mean) decreased for patients who received duloxetine (60 mg daily) compared total score (least square mean) decreased for patients who received duloxetine (60 mg daily) compared with patients who received placebo at all visits starting in week14 ( with patients who received placebo at all visits starting in week14 (P P4 40.001). HRSD 0.001). HRSD 17 17 ,17=item Hamilton Rating ,17=item Hamilton Rating Scale for Depression. Scale for Depression.
relapse. This recommendation is based on relapse. This recommendation is based on data which clearly show the effectiveness data which clearly show the effectiveness of a number of antidepressants in reducing of a number of antidepressants in reducing the risk of depressive relapse. A recent systhe risk of depressive relapse. A recent systematic review of 31 antidepressant trials tematic review of 31 antidepressant trials found that continuation treatment with found that continuation treatment with antidepressant reduced the odds of depresantidepressant reduced the odds of depressive relapse by 70% compared with plasive relapse by 70% compared with placebo (Geddes cebo (Geddes et al et al, 2003) . Another recent , 2003) . Another recent literature review estimated relapse rates of literature review estimated relapse rates of approximately 33-50% in patients for approximately 33-50% in patients for whom antidepressant treatment whom antidepressant treatment is not is not maintained, compared with only maintained, compared with only 10-10-15% in patients who receive continued 15% in patients who receive continued treatment (Hirschfeld, 2001) . It must theretreatment (Hirschfeld, 2001) . It must therefore be possible to demonstrate that an fore be possible to demonstrate that an antidepressant has the ability to prevent antidepressant has the ability to prevent relapses of depression as well as having relapses of depression as well as having efficacy in the acute treatment of a depresefficacy in the acute treatment of a depressive episode. In the present study, after 12 sive episode. In the present study, after 12 weeks of acute treatment with duloxetine weeks of acute treatment with duloxetine (60 mg daily), 82.6% of patients who (60 mg daily), 82.6% of patients who were randomised to continue duloxetine were randomised to continue duloxetine treatment at the same dose for a further treatment at the same dose for a further 26 weeks remained relapse-free, compared 26 weeks remained relapse-free, compared with 71.5% of patients who were randomwith 71.5% of patients who were randomised to placebo. This is a statistically ised to placebo. This is a statistically and clinically significant difference which and clinically significant difference which demonstrates the efficacy of duloxetine in demonstrates the efficacy of duloxetine in the prevention of depressive relapse. These the prevention of depressive relapse. 
Symptom resolution Symptom resolution
The patient's expectation of antidepressant The patient's expectation of antidepressant therapy is resolution of the full spectrum of therapy is resolution of the full spectrum of depressive symptoms, and resolution of depressive symptoms, and resolution of both the emotional and somatic symptoms both the emotional and somatic symptoms associated with depression is increasingly associated with depression is increasingly being recognised as an important treatment being recognised as an important treatment goal (Fava, 2002) . During the continuation goal (Fava, 2002) . During the continuation phase of this study, when compared with phase of this study, when compared with patients who received placebo treatment, patients who received placebo treatment, participants who received duloxetine participants who received duloxetine (60 mg daily) experienced better mainte-(60 mg daily) experienced better maintenance of efficacy as assessed by multiple nance of efficacy as assessed by multiple clinician-rated and patient self-reported clinician-rated and patient self-reported measures of both emotional symptoms (inmeasures of both emotional symptoms (including the HRSD cluding the HRSD 17 17 total score, multiple total score, multiple sub-scales of the HRSD sub-scales of the HRSD 17 17 , PGI-I and , PGI-I and CGI-S) and somatic symptoms (including CGI-S) and somatic symptoms (including the HRSD the HRSD 17 17 item 13 (somatic-general), item 13 (somatic-general), the SQ-SS, and 4 out of 5 measures of the the SQ-SS, and 4 out of 5 measures of the visual analogue scales for pain, namely visual analogue scales for pain, namely headaches, back pain, shoulder pain and headaches, back pain, shoulder pain and pain while awake). In addition, duloxepain while awake). In addition, duloxetine-treated patients reported increased intine-treated patients reported increased interest in daily activities, improved quality terest in daily activities, improved quality of life (as assessed by the QLDS) and deof life (as assessed by the QLDS) and decreased disability (as assessed by the SDS creased disability (as assessed by the SDS total score), compared with patients who total score), compared with patients who received placebo. received placebo.
Transient worsening and adverse Transient worsening and adverse events events
Although patients who were treated with Although patients who were treated with duloxetine had better outcomes on the priduloxetine had better outcomes on the primary outcome measure and on 17 out of 18 mary outcome measure and on 17 out of 18 secondary outcome measures compared secondary outcome measures compared with placebo-treated patients, an unexwith placebo-treated patients, an unexpected finding was the apparent transient pected finding was the apparent transient worsening (as indicated by an increase in worsening (as indicated by an increase in mean HRSD mean HRSD 17 17 total score) of the condition total score) of the condition of patients in both the duloxetine-and of patients in both the duloxetine-and placebo-treated groups for approximately placebo-treated groups for approximately 10 weeks after randomisation, before there 10 weeks after randomisation, before there was a subsequent improvement (Fig. 3) . was a subsequent improvement (Fig. 3) . The cause of this might be related to a possThe cause of this might be related to a possible state of uncertainty and anxiety inible state of uncertainty and anxiety induced in patients who were aware that duced in patients who were aware that after the period of open-label treatment after the period of open-label treatment they had a 50% chance of being randomthey had a 50% chance of being randomised to continuation treatment with plaised to continuation treatment with placebo. Although investigators were also cebo. Although investigators were also blinded to the patients' treatments after blinded to the patients' treatments after randomisation, investigator bias during randomisation, investigator bias during the evaluation of patients might also be imthe evaluation of patients might also be implicated in this observation, and it should plicated in this observation, and it should be noted that the success of blinding for pabe noted that the success of blinding for patients and assessors was not evaluated. A tients and assessors was not evaluated. A further possible explanation for the transifurther possible explanation for the transient worsening of the condition of study ent worsening of the condition of study participants after randomisation is the participants after randomisation is the occurrence of adverse events linked to disoccurrence of adverse events linked to discontinuation in patients who were randomcontinuation in patients who were randomised to placebo. Such adverse events may ised to placebo. Such adverse events may mimic the symptoms of a depressive relapse mimic the symptoms of a depressive relapse if they are sufficiently severe and/or longif they are sufficiently severe and/or longlived, and were not explicitly elicited in this lived, and were not explicitly elicited in this study by a specific scale such as the study by a specific scale such as the Discontinuation, Emergent Signs and Discontinuation, Emergent Signs and Symptoms scale (Rosenbaum Symptoms scale (Rosenbaum et al et al, 1998) . , 1998). Arguing against this possible explanation Arguing against this possible explanation is the observation that transient worsening is the observation that transient worsening after randomisation occurred in patients after randomisation occurred in patients who were randomised to both placebo who were randomised to both placebo and duloxetine, where in the latter and duloxetine, where in the latter group there was no interruption of duloxegroup there was no interruption of duloxetine treatment to permit the appearance tine treatment to permit the appearance 3 51 3 51 AUTHOR'S PROOF AUTHOR'S PROOF , 2002) . In this study, nausea was the most frequently reported nausea was the most frequently reported treatment-linked adverse event during the treatment-linked adverse event during the acute phase. It was most often mild or acute phase. It was most often mild or moderate in severity, and it was reported moderate in severity, and it was reported as a reason for discontinuation for 2.1% as a reason for discontinuation for 2.1% of patients. These findings are consistent of patients. These findings are consistent with the results of previous studies of with the results of previous studies of duloxetine in the acute treatment of duloxetine in the acute treatment of MDD. For those patients who met the entry MDD. For those patients who met the entry criteria and proceeded to the continuation criteria and proceeded to the continuation phase, there were no significant differences phase, there were no significant differences in the frequencies of treatment-linked in the frequencies of treatment-linked adverse event reporting between patients adverse event reporting between patients who received duloxetine and those who who received duloxetine and those who received placebo. The number of adverse received placebo. The number of adverse events was low overall, with only 5 patients events was low overall, with only 5 patients in each treatment group (duloxetine (60 mg in each treatment group (duloxetine (60 mg daily), daily), n n¼136; placebo, 136; placebo, n n¼142) reporting 142) reporting adverse events as reasons for discontinuaadverse events as reasons for discontinuation. Among patients in whom duloxetine tion. Among patients in whom duloxetine (60 mg daily) was well tolerated (as evi-(60 mg daily) was well tolerated (as evidenced by completion of the 12-week acute denced by completion of the 12-week acute phase) and efficacious (as evidenced by phase) and efficacious (as evidenced by meeting the criteria for entry into the contimeeting the criteria for entry into the continuation phase), only 3.6% reported any nuation phase), only 3.6% reported any treatment-linked adverse events as reasons treatment-linked adverse events as reasons for discontinuation over the next 26 weeks for discontinuation over the next 26 weeks of the study. During both the acute phase of the study. During both the acute phase and the continuation phase, duloxetine and the continuation phase, duloxetine treatment of patients with MDD was not treatment of patients with MDD was not associated with clinically important associated with clinically important changes in cardiovascular function or changes in cardiovascular function or laboratory results between baseline and laboratory results between baseline and the end-point. Although in some cases there the end-point. Although in some cases there were statistically significant changes in were statistically significant changes in some parameters, these changes were of some parameters, these changes were of small magnitude and were not clinically small magnitude and were not clinically significant, which suggests that overall significant, which suggests that overall duloxetine is well tolerated during longduloxetine is well tolerated during longterm therapy, and that its treatment-linked term therapy, and that its treatment-linked adverse event profile is similar to that adverse event profile is similar to that reported previously for duloxetine in acute reported previously for duloxetine in acute trials and for marketed selective serotonin trials and for marketed selective serotonin reuptake inhibitors (SSRIs). reuptake inhibitors (SSRIs).
Strengths and limitations Strengths and limitations
Particular strengths of this study include the Particular strengths of this study include the following: the relatively large sample size following: the relatively large sample size compared with that of similar studies; the compared with that of similar studies; the similarity of the acute phase to clinical similarity of the acute phase to clinical practice by virtue of the use of open-label practice by virtue of the use of open-label treatment; the reduction of bias during treatment; the reduction of bias during the continuation phase because of the the continuation phase because of the subsequent double-blinding of both pasubsequent double-blinding of both patients and investigators to active treatment tients and investigators to active treatment v v. placebo and the taper of duloxetine for . placebo and the taper of duloxetine for patients who received placebo; the multiple patients who received placebo; the multiple and independent measures of both the emoand independent measures of both the emotional and somatic symptoms associated tional and somatic symptoms associated with MDD; and the evaluation of the effiwith MDD; and the evaluation of the efficacy of dose-doubling as a strategy for cacy of dose-doubling as a strategy for patients who are experiencing relapse (to patients who are experiencing relapse (to be discussed elsewhere). be discussed elsewhere).
The limitations of the study include the The limitations of the study include the fact that the design did not address the fact that the design did not address the comparison of duloxetine with currently comparison of duloxetine with currently available antidepressants. In addition, available antidepressants. In addition, caution should be exercised when extracaution should be exercised when extrapolating the results reported here (and polating the results reported here (and in most clinical trials) to clinical practice, in most clinical trials) to clinical practice, as the patients in this study may not be as the patients in this study may not be entirely representative of the general entirely representative of the general clinical population for a number of reaclinical population for a number of reasons, including the use of inclusion and exsons, including the use of inclusion and exclusion criteria during the selection of clusion criteria during the selection of study participants, and the number and frestudy participants, and the number and frequency of study visits, neither of which are quency of study visits, neither of which are representative of typical clinical practice. representative of typical clinical practice. Continuation treatment with duloxetine (60 mg daily) was not associated with the occurrence of adverse events at a greater frequency than that seen with placebo occurrence of adverse events at a greater frequency than that seen with placebo treatment. treatment.
LIMITATIONS LIMITATIONS
& & Caution should be exercised when extrapolating these results to general clinical Caution should be exercised when extrapolating these results to general clinical practice, because of the highly selected nature of the population that was studied. practice, because of the highly selected nature of the population that was studied. Discontinuation-linked adverse events may mimic some signs of depressive relapse, and were not specifically elicited in this study. relapse, and were not specifically elicited in this study.
